You are here

Human Performance Optimization

Award Information
Agency: Department of Defense
Branch: Special Operations Command
Contract: H9240521C0015
Agency Tracking Number: S2S-0012
Amount: $1,499,581.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: SOCOM17C-001
Solicitation Number: 17.C
Timeline
Solicitation Year: 2017
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-09-07
Award End Date (Contract End Date): 2023-09-14
Small Business Information
10210 Campus Point Dr #150
San Diego, CA 92121-1111
United States
DUNS: 080085661
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Noah Davidsohn
 (858) 695-4876
 sbir@socom.mil
Business Contact
 Daniel Oliver
Phone: (916) 396-3714
Email: dan@rejuvenatebio.com
Research Institution
 Jackson Laboratory
 laure case
 
600 main street
bar harbor, ME 04609-1522
United States

 (207) 288-6000
 Domestic Nonprofit Research Organization
Abstract

Special Operations Forces (SOF) are an integral aspect of the US military. SOF operators are among the most elite and highly qualified individuals in the U.S. military. As such, extraordinary physical and mental demands are placed upon them to excel in extreme environments for extended periods of time. This unrelenting cycle of combat deployments and intense pre-deployment training shortens the functional life for extended periods of time. This unrelenting cycle of combat deployments and intense pre-deployment training shortens the functional life of operators, a highly undesirable outcome. Rejuvenate Bio developed a gene therapy platform that identified genes that can increase the stress-resistance, health and lifespan of mice as well as mitigate three different age-related diseases (heart failure, diabetes and obesity). We believe that these novel gene therapies will also enhance performance due to their modulations of stress responses and metabolic energy pathways. As a first step toward developing therapies for humans, we propose to measure the effect of these gene therapies on endurance, speed of recovery, and resistance to muscle damage. Completion of this Phase I study will enable us to begin Phase II testing of these therapies’ ability to enhance performance in a large animal model (canines). Using aging as a model to discover performance enhancing genes will allow for increased performance now and far into the future.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government